細胞培養基市場 - 按產品類型（無血清培養基 {CHO、HEK 293、BHK}、幹細胞培養基）、應用（生物製藥生產 {疫苗、單株抗體}、診斷）、最終用戶 - 全球預測（2024 - 2032）

細胞培養基市場規模預計從 2024 年到 2032 年將以 12.8% 的複合年成長率擴大。技術的發展，包括 3D 細胞培養和幹細胞研究的創新，正在推動對先進培養基配方的需求。

對慢性疾病，特別是癌症的研究不斷增加，也刺激了對細胞培養基的需求。根據美國國家癌症研究所的資料，到2024 年，美國將診斷出約2,001,140 例新癌症病例。 。

整個市場分為產品類型、應用、最終用戶和地區。

根據產品類型，由於個人化醫療需求不斷增加、再生醫學和幹細胞研究的進步，特種培養基領域的細胞培養基市場預計將在 2024 年至 2032 年間大幅成長。專業配方對於精確的細胞環境以及支持標靶治療和複雜細胞培養技術的開發至關重要。生物製藥研發投資的不斷增加以及對高品質、可重複結果的需求不斷成長正在推動該領域的成長。

在疾病診斷和個人化醫療不斷擴大的研究的帶動下，診斷應用領域的細胞培養基產業將從 2024 年到 2032 年以顯著的速度成長。細胞培養基在培養患者來源的細胞以進行診斷測試、生物標記發現和藥物敏感性測定方面發揮著至關重要的作用。此外，分子診斷的進步和慢性病的日益普及刺激了對適合診斷應用的準確可靠的細胞培養基配方的需求。

從地區來看，由於生物製藥產業的擴張，特別是在中國和印度等國家，預計到 2032 年，亞太地區細胞培養基市場將呈現強勁成長。對醫療基礎設施和研究設施的投資不斷增加。先進細胞培養技術的日益普及以及對個人化醫療的認知不斷增強，正在加速產品的部署。政府推出的有利措施以及與國際生物技術公司的合作也正在推動區域市場的發展。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性病發生率上升
    • 細胞培養基技術的進步
    • 對無血清和動物成分培養基的需求不斷增加
    • 再生醫學需求不斷成長
  • 產業陷阱與挑戰
    • 細胞生物學產品成本高
    • 嚴格的監管挑戰
• 成長潛力分析
• 新興科技格局
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司定位矩陣
• 戰略儀錶板

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

• 主要趨勢
• 無血清培養基
  • CHO媒體
  • HEK 293 媒體
  • BHK媒體
  • VERO細胞培養基
  • 昆蟲細胞培養基
  • 免疫細胞培養基
  • 其他無血清培養基
• 專業媒體
• 化學成分確定的培養基
• 幹細胞培養基
• 其他產品類型

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 生物製藥生產
  • 單株抗體
  • 疫苗生產
  • 其他生物製藥產品
• 診斷
• 藥物篩選與開發
• 組織工程與再生醫學
• 研究目的
• 其他應用

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

• 主要趨勢
• 製藥和生物技術公司
• 醫院和診斷實驗室
• 研究和學術機構
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021-2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 9 章：公司簡介

• ACROBiosystems
• Corning Incorporation
• Danaher Corporation
• FUJIFILM Irvine Scientific
• Lonza Group
• Merck KGaA
• Miltenyi Biotech
• Nuvonis
• Sartorius AG
• ScienCell Research Laboratories
• Thermo Fisher Scientific Inc.

Cell Culture Media Market size is projected to expand at 12.8% CAGR from 2024 to 2032. The rising demand for biopharmaceuticals, such as vaccines and monoclonal antibodies is necessitating the use of high-quality cell culture media in production processes. Technological developments, including the innovations in 3D cell cultures and stem cell research are driving the need for advanced media formulations.

The increasing research on chronic diseases, particularly cancer is also fueling the demand for cell culture media. As per data from the National Cancer Institute, in 2024, around 2,001,140 new cases of cancer will be diagnosed in the U.S. The expanding fields of regenerative medicine and tissue engineering is increasing the funding from government and private sectors for cell-based research, driving the industry growth.

The overall market is segregated into product type, application, end-user, and region.

Based on product type, the cell culture media market from the specialty media segment is estimated to rise at significant rate between 2024 and 2032, due to the increasing demand for personalized medicine, advancements in regenerative medicine, and stem cell research. Specialized formulations are essential for precise cellular environments as well as supporting the development of targeted therapies and complex cell culture techniques. The rising investments in biopharmaceutical R&D and the growing need for high-quality, reproducible results are driving the segment growth.

Cell culture media industry from the diagnostics application segment will grow at notable rate from 2024 to 2032, led by the expanding research in disease diagnostics and personalized medicine. Cell culture media is serving a crucial role in culturing patient-derived cells for diagnostic testing, biomarker discovery, and drug sensitivity assays. Moreover, the advancements in molecular diagnostics and the growing prevalence of chronic diseases are spurring the demand for accurate and reliable cell culture media formulations tailored to diagnostic applications.

Regionally, the Asia Pacific cell culture media market is anticipated to depict robust growth through 2032, owing to the expansion of the biopharmaceutical sector, particularly in countries like China and India. There have been rising investments in healthcare infrastructure and research facilities. The increasing adoption of advanced cell culture technologies, and growing awareness about personalized medicine is accelerating the product deployment. The launch of favorable government initiatives and collaborations with international biotech companies are also driving the regional market progression.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases
    • 3.2.1.2 Advancement in cell culture media technology
    • 3.2.1.3 Increasing demand for serum and animal component-free media
    • 3.2.1.4 Growing demand for regenerative medicine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of cell biology products
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Emerging technology landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company positioning matrix
• 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Serum-free media
  • 5.2.1 CHO media
  • 5.2.2 HEK 293 media
  • 5.2.3 BHK media
  • 5.2.4 VERO cell media
  • 5.2.5 Insect cell media
  • 5.2.6 Immune cell media
  • 5.2.7 Other serum-free media
• 5.3 Specialty media
• 5.4 Chemically defined media
• 5.5 Stem cell culture media
• 5.6 Other product types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Biopharmaceutical production
  • 6.2.1 Monoclonal antibodies
  • 6.2.2 Vaccine production
  • 6.2.3 Other biopharmaceutical productions
• 6.3 Diagnostics
• 6.4 Drug screening and development
• 6.5 Tissue engineering and regenerative medicine
• 6.6 Research purpose
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Hospital and diagnostic laboratories
• 7.4 Research and academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 ACROBiosystems
• 9.2 Corning Incorporation
• 9.3 Danaher Corporation
• 9.4 FUJIFILM Irvine Scientific
• 9.5 Lonza Group
• 9.6 Merck KGaA
• 9.7 Miltenyi Biotech
• 9.8 Nuvonis
• 9.9 Sartorius AG
• 9.10 ScienCell Research Laboratories
• 9.11 Thermo Fisher Scientific Inc.